Skip to main content
. Author manuscript; available in PMC: 2011 Sep 16.
Published in final edited form as: J AIDS Clin Res. 2011 Feb 18;2(117):1000117. doi: 10.4172/2155-6113.1000117

Table 2.

Patterns of reverse transcriptase drug resistance mutations

Number of drug resistance mutations (n pts) Months on ART Sex VL at study enrollment (copies/mL) CD4 at study enrollment (cells/mm3) NNRTI NRTI
≥5 (n=8 pts)

1* 48 F 3 010 524 K101E+V108I+Y181C D67N+K70R+M184V+K219E
2** 49 F 2 680 213 K101H+K103N+V106M+G190A+F227L D67N+M184V
3*,^ 41 F 4310 354 K101E+V106M+G190A D67N+M184V
4 44 F 75 000 89 K103N+P225H D67N+K70R+M184V+T215F+K219E
5* 22 F 1850 342 K103N+V108I A62V+V75I+M184V
6* 45 F 773 384 V106M+G190A M41L+D67N+K70R+M184V
7* 44 F 2 530 199 V106M+Y188LH D67N+M184V+K219E
8 45 F 18 200 496 V106M+Y188L M41L+D67N+K70R+M184V+T215Y

4 (n=6 pts)

9 15 F 16 900 160 K101E+V108I+G190A M184V
10 45 F 11 000 464 K101H+K103N+G190A M184V
11 46 F 3 000 354 K103N+P225H V75I+M184V
12* 37 M 49 900 16 K103N+Y181C+P225H M184I
13^ 47 F 54 700 419 K103N+G190A+P225H M184V
14 47 F 9 670 377 K103N+V106A+G190A K65R

3 (n=10 pts)

15* 48 F 18 300 331 K101E+Y188L M184I
16 13 F 6 890 214 K101E+V106M M184V
17 41 F 5 340 319 K103N D67N+M184V
18* 46 F 407 269 K103N+P225H M184V
19 47 F 6 510 190 K103N+V108I M184V
20* 47 F 1 330 277 K103N+V108I M184V
21 47 M 31 000 99 K103N+V108I M184V
22** 47 F 1 280 642 K103N+V106M M184V
23* 40 F 955 276 V106M A62V+M184V
24 84 F 43 800 174 V106M+Y188C M184V

2 (n=2 pts)

25 43 M 430 151 K103N M184V
26**,^ 47 F 1 370 320 K103N M184V

1 (n=5 pts)

27** 44 M 178 000 47 K103N ---
28** 46 F 56 500 187 K103N ---
29** 45 F 42 800 100 K103N ---
30* 45 M 1 130 439 K103N ---
31^ 46 F 43 900 193 K103N ---

No major mutations (n=7 pts)

32 46 F 552 369 No major mutations No major mutations
33** 41 F 882 000 90 No major mutations No major mutations
34** 47 F 1450 192 No major mutations No major mutations
35*,^ 43 M 83 000 103 No major mutations No major mutations
36^ 47 F 77 500 232 No major mutations No major mutations
37**,^ 43 M 312 000 203 No major mutations No major mutations
38^ 50 M 493 000 157 No major mutations No major mutations

Not amplifiable (n=5 pts)

39 44 F 463 357 --- ---
40*,^ 43 F 4 660 554 --- ---
41**,^ 41 M 1 060 430 --- ---
42** 13 F 557 445 --- ---
43** 55 F 66 800 379 --- ---

Pts, patients; W, woman; M, man; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI, VL: virus load

Pts, patients; F, female; M, male; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI, VL: virus load

*

Persistent virologic ailure at follow-up

**

Re-suppressed at follow-up

^

Came late >7 days for the last drug-refill visit